Azathioprine (AZA)

DRUG7 trials

Conditions

Alopecia AreataAlopecia Areata(AA)Genetic PolymorphismMucopolysaccharidosis INeuromyelitis Optica Spectrum DisorderRelapsing PolychondritisUlcerative ColitisUlcerative Colitis (UC)

Phase 1

Immune Tolerance Study With Aldurazyme® (Laronidase)

CompletedNCT00741338

Genzyme, a Sanofi CompanyMucopolysaccharidosis I

Start: 2008-09-30End: 2012-09-30Updated: 2014-07-02

Phase 2

To Compare the Efficacy of Weekly Azathioprine Pulse Versus Betamethasone Oral Mini-Pulse in the Treatment of Moderate to Severe Alopecia Areata

CompletedNCT06786689

Sheikh Zayed Medical CollegeAlopecia Areata, Alopecia Areata(AA)

Start: 2023-03-01End: 2023-09-30Updated: 2025-01-22

An Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis

RecruitingNCT06941376

University of PennsylvaniaRelapsing Polychondritis

Start: 2025-08-01End: 2027-12-01Target: 20Updated: 2026-02-04

Phase 3

Efficacy & Safety of Infliximab Monotherapy Vs Combination Therapy Vs AZA Monotherapy in Ulcerative Colitis (Part 1) Maintenance Vs Intermittent Therapy for Maintaining Remission (Part 2)(Study P04807)

TerminatedNCT00537316

Merck Sharp & Dohme LLCUlcerative Colitis

Start: 2007-07-31End: 2010-02-28Updated: 2017-04-12

A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)

CompletedNCT04660539

Hoffmann-La RocheNeuromyelitis Optica Spectrum Disorder

Start: 2021-03-02End: 2024-05-28Updated: 2024-12-27

Phase 4

Efficacy of Top-down Therapy With Mirikizumab Versus Standard of Care With Azathioprine in Patients With Newly Diagnosed Moderate-to-severe Ulcerative Colitis

RecruitingNCT07235904

University Hospital Schleswig-HolsteinUlcerative Colitis (UC)

Start: 2025-12-05End: 2028-10-31Target: 300Updated: 2025-12-16

Unknown Phase

The Frequency of Thiopurine Methyltransferase Polymorphism in Systemic Lupus Erythematosus SLE

CompletedNCT07012239

Bangladesh Medical UniversityGenetic Polymorphism

Start: 2016-01-01End: 2018-01-01Updated: 2025-06-10

2025-07-311 citations

Analysis of infection rates in neuromyelitis optica spectrum disorder: Comparing satralizumab treatment in SAkuraMoon, post-marketing, and US-based health claims data.

2025-04-191 citations

Safety and Effectiveness of Satralizumab in Japanese Patients with Neuromyelitis Optica Spectrum Disorder: A 6-month Interim Analysis of Post-marketing Surveillance.

2024-07-165 citations

Long-term Efficacy of Satralizumab in Adults with Aquaporin-4-IgG-seropositive (AQP4-IgG+) Neuromyelitis Optica Spectrum Disorder (NMOSD): Results from SAkuraMoon (S5.001)

Neurology2023-04-251 citations

Long-term Safety of Satralizumab in Adults with Aquaporin-4-IgG-seropositive (AQP4-IgG+) Neuromyelitis Optica Spectrum Disorder (NMOSD): Results from SAkuraMoon (P13-5.002)

Neurology2023-04-25

Immune tolerance induction for laronidase treatment in mucopolysaccharidosis I.

2017-01-1312 citations

Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis.

2014-02-01646 citations